Paolo Michieli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3876953/publications.pdf

Version: 2024-02-01

37	3,775	304743	414414
papers	citations	22 h-index	32 g-index

38	38	38	4870
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3, 347-361.	16.8	1,244
2	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 1998, 391, 285-288.	27.8	485
3	Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.. Journal of Clinical Investigation, 1993, 91, 1753-1760.	8.2	333
4	Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 2004, 6, 61-73.	16.8	282
5	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. Clinical Cancer Research, 2013, 19, 2381-2392.	7.0	157
6	Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene, 1999, 18, 5221-5231.	5.9	139
7	A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met. Journal of Biological Chemistry, 2008, 283, 21267-21277.	3.4	107
8	Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14379-14383.	7.1	96
9	Different point mutations in the met oncogene elicit distinct biological properties. FASEB Journal, 2000, 14, 399-406.	0.5	93
10	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 2014, 7, 1940-1955.	6.4	90
11	An uncleavable form of proâ€“scatter factor suppresses tumor growth and dissemination in mice. Journal of Clinical Investigation, 2004, 114, 1418-1432.	8.2	85
12	Expression and Functional Regulation of Myoglobin in Epithelial Cancers. American Journal of Pathology, 2009, 175, 201-206.	3.8	74
13	Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody. Journal of Biological Chemistry, 2010, 285, 36149-36157.	3.4	73
14	Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?. Cell Cycle, 2009, 8, 3291-3296.	2.6	60
15	Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs. Cancer Research, 2014, 74, 6598-6609.	0.9	59
16	Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. Journal of Clinical Investigation, 2009, 119, 865-875.	8.2	59
17	Four individually druggable MET hotspots mediate HGF-driven tumor progression. Journal of Clinical Investigation, 2014, 124, 3172-3186.	8.2	42
18	Mutations in the met Oncogene Unveil a â€œDual Switchâ€•Mechanism Controlling Tyrosine Kinase Activity. Journal of Biological Chemistry, 2003, 278, 29352-29358.	3.4	41

#	Article	IF	Citations
19	Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis. PLoS ONE, 2008, 3, e3223.	2.5	36
20	Tivantinibâ€"a cytotoxic drug in MET inhibitor's clothes?. Nature Reviews Clinical Oncology, 2013, 10, 372-374.	27.6	34
21	Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Research, 2015, 75, 3373-3383.	0.9	32
22	METPRC mutations in the ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. , 1999, 181, 507-514.		24
23	An HGFâ€"MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nature Biotechnology, 2002, 20, 488-495.	17.5	22
24	Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. Oncotarget, 2017, 8, 38193-38213.	1.8	22
25	Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy. Scientific Reports, 2016, 6, 31621.	3.3	16
26	Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology, 2008, 47, 2010-2025.	7.3	15
27	HGFâ€"MSP chimera protects kidneys from ischemiaâ€"reperfusion injury. Biochemical and Biophysical Research Communications, 2007, 363, 451-456.	2.1	14
28	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METâ€"Response. Clinical Cancer Research, 2013, 19, 4291-4291.	7.0	12
29	Dual Constant Domainâ€Fab: A novel strategy to improve halfâ€life and potency of a Met therapeutic antibody. Molecular Oncology, 2016, 10, 938-948.	4.6	11
30	Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. Journal of Molecular Medicine, 2014, 92, 65-76.	3.9	9
31	TaqI RFLP of the human tropomyosin gene (TPM3) involved in the generation of the TRK oncogene. Nucleic Acids Research, 1991, 19, 4796-4796.	14.5	5
32	The NHanceÂ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. Biomedicines, 2021, 9, 665.	3.2	2
33	ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment.. Journal of Clinical Oncology, 2016, 34, e14016-e14016.	1.6	2
34	Abstract 631: Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. , 2011, , .		0
35	Abstract B082: Role of CD44v6 in acquired resistance to anti-angiogenic therapy of triple-negative breast cancer. , 2013, , .		0
36	Abstract LB-330: Four individually druggable Met hotspots mediate HGF-driven tumor progression. , 2014, , .		0

#	Article	IF	Citations
37	Abstract 3726: Inhibition of MET overcomes invasive resistance to Bevacizumab and prolongs survival in orthotopic mouse models of glioblastoma multiforme. , 2014, , .		0